The role of exercise in modifying outcomes for people with multiple sclerosis: a randomized trial by unknown
Mayo et al. BMC Neurology 2013, 13:69
http://www.biomedcentral.com/1471-2377/13/69STUDY PROTOCOL Open AccessThe role of exercise in modifying outcomes for
people with multiple sclerosis: a randomized trial
Nancy E Mayo1*, Mark Bayley2, Pierre Duquette3, Yves Lapierre4, Ross Anderson5 and Susan Bartlett1Abstract
Background: Despite the commonly known benefits of exercise and physical activity evidence shows that persons
Multiple Sclerosis (MS) are relatively inactive yet physical activity may be even more important in a population
facing functional deterioration. No exercise is effective if it is not done and people with MS face unique barriers to
exercise engagement which need to be overcome. We have developed and pilot tested a Multiple Sclerosis
Tailored Exercise Program (MSTEP) and it is ready to be tested against general guidelines for superiority and
ultimately for its impact on MS relevant outcomes. The primary research question is to what extent does an MS
Tailored Exercise Program (MSTEP) result in greater improvements in exercise capacity and related outcomes over a
one year period in comparison to a program based on general guidelines for exercise among people with MS who
are sedentary and wish to engage in exercise as part of MS self-management.
Methods/Design: The proposed study is an assessor-blind, parallel-group, randomized controlled trial (RCT). The
duration of the intervention will be one year with follow-up to year two. The targeted outcomes are exercise
capacity, functional ambulation, strength, and components of quality of life including frequency and intensity of
fatigue symptoms, mood, global physical function, health perception, and objective measures of activity level.
Logistic regression will be used to test the main hypothesis related to the superiority of the MSTEP program based
on a greater proportion of people making a clinically relevant gain in exercise capacity at 1 year and at 2 years,
using an intention-to-treat approach. Sample size will be 240 (120 per group).
Discussion: The MS community is clearly looking for interventions to help alleviate the disabling sequelae of MS
and promote health. Exercise is a well-known intervention which has known benefits to all, yet few exercise
regularly. For people with MS, the role of exercise in MS management needs to be rigorously assessed to inform
people as to how best to use exercise to reduce disability and promote health.
Trial registration: Clinical Trials.gov: NCT01611987Background
Multiple Sclerosis (MS) is a progressive and chronic dis-
ease affecting many North American young adults who
are at the peak of their career and family development
[1-6]. Persons with MS commonly report problems with
walking, balance, fatigue and visual disturbances [5,6].
These symptoms can appear suddenly, they have a vari-
able course and they differ in severity. They all, however,
progress with age and ultimately can have a devastating
impact on the health and quality of life [7-9].* Correspondence: nancy.mayo@mcgill.ca
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reproduction in any medium, provided the orThe cause of MS is unknown and the cure is yet to be
found. Technological advances such as the MRI, however,
have made early diagnosis possible. New medications slow
disease progression, usually only in the relapsing-remitting
variant of the disease not the primary progressive or sec-
ondary progressive forms [6,10,11]. The full benefits of
advances in diagnosis and treatment will not be realized
unless people with MS are encouraged to develop and
maintain a level of physical conditioning that will allow
them to live full lives. In addition, there is growing consen-
sus that exercise could exert an immunomodulation role
which could be neuroprotective [12-14]. Therefore, some
therapeutic exercise could be neurorehabilitative, as with
people with stroke [15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physical activity participation [16-18], evidence shows that
persons with MS participate in physical activity at a level
more than ½ standard deviation below that of a non-MS
population (effect size −0.60; 95% CI: -0.44 to −0.77) [19].
Hence, persons with MS (predominantly women) may
adopt a sedentary lifestyle with the added risk of develop-
ing secondary health conditions such as heart disease,
osteoporosis, obesity, and diabetes. The role of exercise
and physical activity may be even more important in a
population facing functional deterioration [14,19,20].
We recently updated [21] a 2004 Cochrane Review
[22] and summarized the results 11 randomized trials on
exercise with a combined total of 502 persons with MS.
The focus of this review was on evidence for prescribing
exercise and the conclusion was that, due to the broad
range of exercise interventions, it is not possible to make
unified exercise recommendation as to what type of
exercise is safe and effective for persons with MS. The
studies covered four main types of exercise (i) aerobic ex-
ercise (walking, bicycling, and aquatic exercise); (ii) yoga;
(iii) resistance exercise; or (iv) stretching. The duration of
the interventions ranged from 3 weeks to 6 months, lasted
30 to 60 minutes per session, and the intervention fre-
quency ranged from one to five times a week with differ-
ent levels of intensity. Only one of the 11 studies reported
an effect size with a 95% confidence interval excluding the
null value of no difference between groups. Literature
published subsequent to our 2009 review [23-31] has not
clarified the role of exercise in MS. A recent (2011) study
by Collet [27] tested 3 different exercise intensities of cyc-
ling exercise on change in walking capacity. There was no
significant gain in walking capacity for the group (n = 20)
assigned to continuous cycling at 45% peak power. The
group assigned to 30 sec. on and 30 sec. off at 90% peak
power (n = 18) showed an increase in distance walked in 2
minutes (2MWT) of 13 m (95% CI 4 to 22); the group
receiving a combination of these two approaches (n = 17)
showed no significant gain on 2MWT. This research sup-
ports the use of high intensity interval training for people
with MS. There was a drop off in attendance after the 6
week program and no further gains were made. The inter-
mittent group with alternating high intensity cycling and
rest experienced some leg pain when cycling.
However, there is evidence for the effectiveness of
various components of exercise in MS [23,25,32,33].
Two studies [32,33] demonstrated that aerobic exercise
in comparison to no aerobic exercise increased VO2
peak and related parameters. Three studies clearly demon-
strated the effectiveness of strength training [23], endur-
ance training [25], and power training [34]. There are new
studies [35-38] showing that pelvic floor exercises, part of
the core musculature, are effective in improving urinary
incontinence for women.At the moment, there is insufficient evidence for pre-
scribing comprehensive exercise programs for people
with MS [21] either for functional improvement or
health promotion, let alone for immunomodulation.
However, several groups have made general recommen-
dations for exercise [14,18,22,39-42]. The most recent
guidelines were produced in 2012 [43] and recommend
30 minutes of moderate intensity aerobic activity, 2 times
per week, and strength training exercises for major muscle
group, 2 times per week.
The MS Societies of Canada, United States, Great
Britain and Australia all provide documentation about
the benefits of exercise for people with MS. But exercise
is not effective if people will not do it.
We recently surveyed 417 persons with MS [44] and
found that 40% were not exercising on a regular basis;
not vastly different some reports from surveys of the
general population [45]. The top three barriers to exer-
cise were being too tired (86%), having MS related im-
pairments (61%), and lack of time (58%). Barriers such
as lack of interest, lack of information regarding exercise
recommendation, interference with other responsibilities;
feeling I can’t do things correctly; dislike exercise; and
find exercise boring, were more commonly endorsed by
non-exercisers than exercisers. This suggests that if non-
exercisers are to be engaged in regular exercise, the pro-
gram must be interesting, relevant to the individual, and
easily implemented across a variety of settings. However
what was missing for people with MS that is different for
people without MS is that people with MS expressed the
need to feel safe and have clear professional instructions
provided on proper techniques, intensity and duration.
In addition, our recently completed study of the life
impact of MS [46] showed, for a sample of 185 persons
diagnosed since 1994, that static balance, physical function
and functional walking capacity (six minute walk test)
were within 70% of norms for age and sex, but individuals
in the sample were < 50%ile for central core strength, grip
strength, and muscle power, and < 25%ile for upper body
core strength and exercise capacity (i.e., peak V02). In
addition, almost ¼ of the sample had spasticity that would
complicate exercise prescription requiring an adapted
exercise program. These findings suggest that in people
with MS, although some have generalized weakness and
deconditioning, the majority have specific problems that
require tailored exercise solutions.
Objectives
The global aim of this study is to contribute evidence for
the role of targeted exercise in altering MS outcomes
over time. The primary research question is to what
extent does an MS Tailored Exercise Program (MSTEP)
result in greater improvements in exercise capacity and
related outcomes over a one year period in comparison
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among people with MS who are sedentary and wish to
engage in exercise as part of MS self-management. The
primary outcome for this question is exercise capacity
measured using cycle ergometry. However exercise effi-
ciency, functional ambulation, strength, components of
quality of life including frequency and intensity of fa-
tigue symptoms, mood, global physical function, and
health perception will also be measured as components
of a global response outcome. The first confirmatory
hypothesis is that MSTEP will result in a greater propor-
tion of people making clinically relevant gains (at least
10% change) in exercise capacity than with general
guidelines after 12 months of intervention; a secondary
hypothesis is that, while there may be some decline in
exercise capacity among individuals from end of inter-
vention to follow-up one year later, the decline will be
greater in the general guideline group augmenting the
difference between groups in the proportion making
10% change from study entry to 24 months. In other
words, gains will be maintained more for the MSTEP
group over the general guideline group.
An exploratory hypothesis is that more of the targeted
outcomes will improve with the MSTEP program than
the general guideline approach. An explanatory hypothesis
is that these gains will be accompanied by reports of
greater exercise self-efficacy (confidence) with the MSTEP
program than with the general guideline program leading




The proposal is for a two-group, assessor-blind, stratified,
randomized, pragmatic, trial. Those consenting will be
randomly assigned with a 1:1 ratio to either the MSTEP
program or the general exercise guideline program. The
intervention period will be one year with follow-up to a
second year. The path of study participants through the
study protocol is shown in Figure 1. The trial is registered
with ClinicalTrials.gov NCT01611987. The trial received
ethical approval from the Montreal Neurological Hospital
Research Ethics Board (NEU-12-005). Written informed
consent will be obtained from all participants in the study.
Participants
The target population is community dwelling, adults
(aged 19 to 65) with MS diagnosed after 1994. Specific
inclusion criteria are: (i) ambulatory (can walk 100 m. be
capable of walking 100 meters without a walking aid
(EDSS ≤ 5.5), even if they do use an aid for daily activities;
and (ii) sedentary or irregularly active at time of study
entry (i.e. do not exercise 30 minutes or more twice per
week of moderate to vigorous activity).Excluded will be people who are (i) unable to speak
and read English or French; (ii) unable to respond to
simple questions on orientation and memory; (iii) have
an additional illness that restricts their function; and/or
(iv) had suffered at least one relapse during the past 30
days (as defined by Polman in 2011 [47]) as this may
affect physical activity/exercise participation. Potential
participants will be identified from the population of
persons enrolled in three MS clinics in the Montreal
area and in three clinics in Toronto.
Interventions
MSTEP
The Multiple Sclerosis Tailored Exercise Program (MSTEP)
was developed based on the results of our systematic
review [21], results of several studies conducted by our
group on the health outcomes and exercise preferences in
people with MS [44,46], pilot experience, knowledge from
both physical therapy practice and exercise training, and
input from patients.
MSTEP was designed to meet the exercise and disability
needs of people with MS, avoid fatigue or heat exhaustion,
as well as to offer the convenience of being able to in-
corporate exercise into a participant’s daily routine (e.g.
performed on their way to work or at a lunch break).
MSTEP provides the person with MS the opportunity to
be taught a program informed by exercise science and
physical therapy including how to safely execute and
adapt a variety of exercises targeting endurance, muscu-
lar and core strength, balance, flexibility, muscular
power, and speed of movement to their needs. The goal
of the MSTEP program is to promote regular bouts of
activity most days per week, encouraging a balance be-
tween rest and activity, and taking into consideration
the physical and emotional status and capacity of the
person which fluctuates from day to day in MS.
There are five primary components to the program:
(i) cardio-aerobic/endurance; (ii) core strength; (iii) per-
ipheral muscle strength; (iv) power; and (v) flexibility.
(i) Cardio aerobic/endurance will be trained using two
types of activities. Cardio-intensive exercise, prescribed,
two times per week will use interval training. We are
calling these days “Push-Days” and have specifically
included interval training as it has been shown it is safe
[48] and can be more effective than continuous endur-
ance training, even in people with chronic health condi-
tions [27,49]. In addition, this type of training empowers
individuals to balance rest, activity, and control (select)
optimal days to work at a high exercise intensity level.
On Push Days, participants will do a short bursts of
moderate-high intensity exercise (e.g., for 1 to 3 minutes)
then reduce to a more comfortable pace for 5–7 minutes.
During demonstration with the exercise instructor, the
intensity of the interval training will be monitored by a
Figure 1 The path of participants through the study protocol.
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how to use the Borg scale with target of 16 (Very hard)
followed by reduced intensity that is comfortable (11-very
light) [50]. Push-days offer a way for subjects to “step-up”
the intensity of the program as a way of increasing
power, strength and endurance. The on/off intensity
intervals will be self-selected working up to 1-on/1-off
over the one year period; a recent study used supervised
30 sec on/30 sec off exercise but the participants experi-
enced leg pain and but did not sustain this when the
program ended. We feel our approach of self-selecting
the intervals would reduce side effects and provides a
challenge for the person lengthen the on-interval and
shorten the off-interval as they increase their exercise
capacity. This activity is done for a minimum of 10 minutes
with progression as tolerated.The second activity, to be done on most other days of
the week (eg. 4), is moderate intensity (brisk) walking,
and we will suggest that they wear a pedometer to moni-
tor progress, beginning with 10 min and working toward
a goal of achieving up to 30 min most days of the week.
To increase variety and options for these walks, individ-
uals can chose to carry light weights, follow metronome
pacing, or use Nordic Walking Poles (which also assist
with balance) or they can choose other forms of exercise
such as swimming or biking. On two other non-Push
Days, participants will choose from a menu of muscular
strength, core strength and balance, or muscular power
and speed of movement exercise options, alternating
each day.
(ii) Core strength will be trained by using adaptations
of exercises commonly taught in courses in Pilates and
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abdominal regions. Persons will be taught to sue differ-
ent pieces of equipment such as an exercise ball, roll or
dome to recruit core muscles as well as simple core
exercises to do without equipment.
Peripheral muscle strength will focus on the major
muscle groups with a particular emphasis on anti-gravity
muscles. Specific exercises will be taught for muscles
that are tested to be weak.
(iii) Power exercises will train strength per unit time
and will focus on muscles required for activities done in
bursts such as stair climbing, rising from a chair, getting
up from the floor, running, and jumping.
(iv) Flexibility exercises will focus at a minimum on calf
muscles (particular important for people with spasticity),
hamstrings, and shoulder girdle muscles. Additional flexi-
bility exercises will be taught for areas assessed to be on
concern (adductors, quadriceps, hip flexors, trunk).
To start each component will be prescribed for 10
minutes with the two cardio-aerobic activities increasing
over time as the participant is able targeting 30 minutes
per day. The MSTEP targets daily (6/7) activity as disabil-
ity does not take a holiday. Flexibility is prescribed 6 days
per week, 60 moderate aerobic exercise such as brisk
walking is prescribed 4 days per week; 120 the other 4
components Push-Day, Core, Strength, Power are pre-
scribed 2 days per week. 60 Thus on anyone day, a person
would do flexibility (10 minutes) and 2 other components
of the person’s choice. We recommend that on the Push-
Day, participants choose a less vigorous activity (eg. Core).
The participants in the MSTEP will have the oppor-
tunity to practice on different types of equipment so that
they may decide for themselves if they wish to purchase
one or more pieces of equipment. They will also be
given photo images or drawings of exercises that have
been tailored to them. They will also be coached with
respect to progression by changing starting position,
duration, support, and inclination. Overall, if the person
can do the exercise, they need to progress.
MSTEP is designed to provide a tailored approach and
part of the intervention is to identify preferred ways of
exercising and preferred times and work with the
participant to develop a personalized exercise schedule.
Participants may wish to join a gym or take a Yoga or
Pilates class and this would be an acceptable way of
working on flexibility, core strength and strength.
Two other aspects of tailoring will be trained: goal set-
ting and implementation intention. Goal setting will follow
the SMART goal approach (Specific, Measureable, Attain-
able, Realistic, and Time specific) [51,52]. Implementation
intention using mental imagery [53,54] to imagine situa-
tions when the participant will not be able to meet their
exercise goal, develop, write out, and visualize these alter-
nate plans.General guideline approach
The control group will be given the 2012 exercise guide-
lines for adults with MS from the Canadian Society for
Exercise Physiology [43] which recommends 30 minutes
of aerobic and strength training two times per week.
Aerobic exercise is gradually increased until 30 minutes is
reached for each workout session and done at a moderate
intensity of 5 or 6 on a scale where 10 is the maximum. At
this intensity, the exerciser could talk but not sing. Exam-
ples of activities are upper or lower body cycling, walking,
elliptical training or aquatic or land exercises.
Strength training could be done on the same or different
day from the aerobic exercise as long as there is one day
rest between strength training sessions. The guideline is to
work up to doing two sets of 10 to 15 repetitions of each
exercise with a rest of one to two minutes in between sets
of exercises. Resistance can be provided by free weights,
cable pulleys, bands, or weight machines. An appropriate
weight is one that can be lifted barely but safely 10 to
15 times.
Elements common to both groups
Both conditions target key components of physical fit-
ness including aerobic capacity and strength. Exercise
progression in both programs is slow and gradual. All
individuals will be taught how to take their heart rate
and work within the age-recommended range, and use
the Borg scale to adjust exercise intensity. The overall
goal is increase physical activity over time in a safe and
effective manner to levels that have been shown to result
in benefits to overall physical fitness and health for
adults with chronic illness.
Participants will be trained in the exercise program to
which they are assigned. Participants in both conditions
will receive two private training sessions with the exer-
cise instructor to assess individual needs and learn how
to apply principles of safe and effective exercise. The
importance of making modifications to accommodate
individual needs and MS in general will be discussed. All
will be provided with a portfolio of exercise instructions.
All participants will be contacted every two weeks dur-
ing the first two months, then monthly thereafter by the
exercise instructor by telephone or email for follow-up
by the instructor. The purpose of follow-up contacts is
to provide an opportunity to ask any questions they have
and also to facilitate long-term retention in the study.
All will have their exercise regimens reviewed during the
intervention year at the evaluations which are scheduled
at 3, 6, and 12 months.
Outcomes
The targeted outcomes are exercise capacity, exercise ef-
ficiency, functional ambulation, strength, and compo-
nents of quality of life including frequency and intensity
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health perception, and illness intrusiveness. Also col-
lected will be exercise adherence, exercise enjoyment,
socio-demographic, adverse events, and clinical informa-
tion including relapse rate. The complete portfolio of
outcomes [55-79] is listed in Table 1.
Primary outcome
The first primary effectiveness outcome will be VO2peak
using a modified Bruce protocol on the cycle ergometer.
Briefly, peak oxygen consumption (VO2peak) will be deter-
mined using an incremental graded cycle ergometer test.
The person will properly seated and the bicycle adjusted
for optimally positioning. Rate of Perceived Exertion
(RPE), heart rate, and blood pressure will be taken at each
workload, in addition to assessing oxygen consumption
and CO2 production. The person will cycle for 3 minutes




Components of Global Outcome
Exercise efficiency: Gross,
net and work efficiency
Gross efficiency = work performed / energy exp
work performed / energy expended above rest
work performed / energy expended above that
Sub-maximal exercise
capacity
The Modified Canadian Aerobic Fitness Test (m
simple to use and inexpensive, that assesses su
Functional ambulation Modified 6 Minute Walk Test (M-6MWT) [60]; di
calculated by [the distance walked in the last m
minute], with ratio ≥ 1.0 indicating less fatigabil
walks, 0.95).
Strength Grip, vertical jump, push-ups, curl-ups [65]
Fatigue symptoms Unidimensional Fatigue Impact Scale [66]; whic
fatigue modeled from the original and modified
Mood* Rand-36 MHI subscale [68,69];
Global physical function* Rand-36 PF subscale [68,69]
Health perception* EQ-5D [70-73]
Quality of life* Patient Generated Index* [74,75]
Explanatory Variables
Current disability level PDDS (patient version of EDSS) for all persons [
Relapses Defined as “patient-reported or objectively obse
CNS, current or historical, with duration of at le
over study period
Exercise adherence Exercise diary (paper, computer version) daily fo
for 1 week every 3 months (see response to rev
Exercise self-efficacy 3 item questionnaire with demonstrated validit
Exercise barriers and
benefits
The benefits subscale of the Exercise Benefits/B
to be independent predictors of exercise engag
* Data from ½ SD from PGI and SF-36 subscales from recently completed CIHR pilo
first publication from this data set [46].subsequently, at intervals of 1 minute, the work load will
be increased by 10 watts. People will be considered to have
reached their peak exertion if one of the following criteria
are met [80]: (i) reached their age-predicted heart rate of
220-age; (ii) a rating of perceived exertion of at least 17 on
the Borg scale; (iii) a respiratory rate of 35 breaths per
minute; (iv) pedalling rate of 50 to 80 repetitions per
minute cannot be maintained; or (v) the person says they
can do no more. Our effectiveness indicator is the propor-
tion of people making a 10% change in VO2peak at the end
of the 12 month intervention.
In addition, each person will also complete, the Modi-
fied Canadian Aerobic Fitness Test (mCAFT) [81],
which is a graded step test and can predict VO2peak
using the regression equation we have recently pub-
lished [46]. This test will be completed only at interim
evaluations (3, 6, and 18 months) or if the person misses
one of the VO2peak assessments.Clinically relevant change
10% change[32,55,56]
ended × 100%, Net efficiency =
× 100%, and Work efficiency =
in cycling at 0 W × 100% [57].
10% change [58].
CAFT) is a multi-stage step-test,
b-maximal aerobic capacity [59].
1 stage [59]
stance and fatigability index
inute ÷ distance walked in the first
ity; Reliability high (ICC across 3
50 m. [32,60-64].
½ SD: jump 5cm; curl ups 5; push
ups 3; grip strength 12 [46].
h is a Rasch validated measure of
versions [60,67]
Minimum clinically important
difference(MCID) 5; ½ SD = 6 [66].
Meaningful change: 10
Meaningful change = 10
Meaningful change = 10
Meaningful change ½ SD = 12.5
76]
rved events typical of an acute inflammatory demyelinating event in the
ast 24 hours, in the absence of fever or infection.” [47]; annualized rate
r 3 months, 1 week every 3 months subsequently; accelerometers worn
iewers on feasibility of this) ActivPal [77]
y and test-retest reliability (>0.85) [78]
arriers Scale will be used [79] along with 4 indicators for barriers shown
ement [21,44]
t grant on Gender differences in Life Impact of MS which is described in the
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A second primary effectiveness outcome will be a global
test based on creating binary response variables for all
relevant outcomes using known clinically meaningful
change to indicate response (or ½ SD if this is not
known [82]) (see Table 1).
Adherence and exercise engagement will be monitored
using a combination of exercise diaries and accelerome-
ters. The exercise diaries are a good short-term method
and also serve as a way for the participants to track their
progress as well as any symptom changes (positive or
negative) such as fatigue or pain. We will use daily diaries
for the first 3 months and subsequently ask people to
complete a diary and wear an accelerometer for one of the
weeks in the month preceding their scheduled assessment.
The weeks for the diary and for the accelerometer will not
coincide.
Sample size
Sample size is based on a test of proportions. Assuming a
range of response proportions in the General Guideline
Group of 0.2 to 0.5, we have powered this study at 80% to
detect a relative risk of >1.5 in favour of the MSTEP
Group (Type I error 0.05). A sample size of 120 per group
(total sample size of 240) is targeted.
Randomization
Randomization will be stratified by site, Montreal and
Toronto and persons will be randomly assigned, within
their strata, either to the MSTEP or General Guidelines
using blocked randomization. The block sizes will be 2,
4 and 6 and the size of the block will also be randomly
assigned. The randomization will be done using web
based program < < http://www.randomization.com.> >
by a statistician who will be the only person with access
to the code. When the outcome assessments have been
completed by the assessment staff, the statistician will
reveal the group assignment to the intervention staff.
Since funding was secured for this trial, there has been
increasing interest in prescribing Fampyra to increase
gait speed and thus an additional strata was created
to avoid having an imbalance of people on Fampyra
(dalfampridine;prolonged-release fampridine tablets)
in one of the groups [83,84].
Blinding
It is not possible to blind the participants as to their
group assignment. Participants were informed that we
were comparing two exercise programs and one was not
presented as potentially superior to the other, protecting
against bias in responses to the self-report outcomes.
Evaluators will be blinded. The main outcome is based
on an assessment of VO2peak which has standard proce-
dures for administration to ensure that the subject putsas much effort as possible into the test. The test is done
off-site using existing personnel who may or may not be
the same for each subject or each assessment within
subject. It is not a test that is strongly affected by
unblinding of the testing staff. Nevertheless, the testing
staff will not be informed of the group assignment. The
situation for the other assessments is similar as they are
performance based tests. These will be done by an
assessment team of students who will vary over time but
also will not be told of the group assignment.
During the analysis, the code for the group assignment
is not revealed until all analyses are completed and
validated.
Statistical methods
The main analysis will be logistic regression to test the
main hypothesis related to the superiority of the MSTEP
program based on a greater proportion of people making
a clinically relevant gain in exercise capacity at 1 year. A
secondary outcome will be the differences in proportions
at 2 years also using logistic regression. The analysis will
be based on intention-to-treat and all persons will be
analysed in the groups to which they were randomized.
A secondary analysis will estimate the impact of exer-
cise on the other relevant outcomes. For this approach,
each outcome will be converted to a binary response
variable based on published clinically meaningful
changes (see Table 1) and generalized estimating equa-
tions (GEE) will be used to test the rate of response in
the MSTEP program to the rate of response in the gen-
eral guideline approach [85,86]. If there is a statistically
significant effect of the intervention, then and only then,
can the effects of the separate outcomes be interpreted
as real [86].
The role of exercise engagement in explaining out-
come variation will be estimated using multivariate
modeling for both logistic and longitudinal growth
models. A separate analysis will be conducted to exam-
ine relapse rate and other adverse events. All of these
analyses will be adjusted for confounders using propen-
sity scoring [27,87-89]. Factors used in the propensity
score are: extent of complaints (co-ordination, weakness
or heaviness in legs, anxiety/depression, bladder prob-
lems), presence of children, and exercise enjoyment at
study entry [44]. Adjustment will also include age and
sex and additional prognostic variables which improve
model fit.
If people are unable to do the VO2peak test or the data
from this test is aberrant (person did not reach a peak),
we will use a validated a regression equation to estimate
VO2peak measured in ml/kg/min from submaximal tests
[46]. The equation, which is based on our pilot work on
60 subjects, is: VO2peak = −11.83 + 1.78(Men) + 0. 2*each
10 meters distance walked in 6 minutes + 16.3 * L/min
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stage of step test.
As is consistent with policy from the funding agency,
Canadian Institutes of Health Research (CIHR), we will
conduct a gender-based analysis for exploratory pur-
poses only. We will also explore whether people with
different relapsing remitting type respond differently
than people with progressive type of MS. This is accom-
plished by fitting an interaction term between group and
gender and group and type of MS. A second sub-group
analysis will explore the impact of the intervention
among people with a different propensity to exercise.
Propensity scoring permits exploration of this variable
on outcomes through stratification by low, medium, and
high values on propensity for exercise interest.
To minimize potential bias arising from missing data
from missing assessments or losses to follow-up, multiple
imputation [90,91] will be carried out on the longitudinal
data for all outcomes with sufficient data. Imputation will
be based on the data arising from key measured variables
and values on the health questionnaires. As is usual, 80
imputed data sets are generated and 20 are chosen (to
maximize dataset independence). Multiple imputation
provides estimates of the value on a missing variable that
would have been recorded if the person had been assessed.
The estimated values incorporate the data that are avail-
able, cross-sectionally and over time, as well as variation
in the multivariate distribution of this existing data. In the
analysis, both the estimate and the associated error, within
and between imputed data sets, are used and the model
error term thus includes the usual sources of error as well
as error arising from imputation. Without this process,
the p-value tends to be underestimated and more likely to
cross the conventional threshold for significance [90,91].Discussion
The MS community is looking for interventions to help
alleviate the disabling sequelae of MS. Exercise is a well-
known intervention which has known benefits to all, it
has no negative side effects when prescribed appropriately,
it has other benefits beyond disability such as reducing
obesity and cardiovascular risk. It is hypothesized to have
neurorehabiliative effects [15] and it is an intervention that
is accessible to all at little cost. Yet, few exercise regularly.
For people with MS, our survey of exercise barriers [44]
showed that a major barrier was in not knowing what to
do, being afraid of heat exhaustion, and fatigue. Proper
instruction and tailoring exercise to specific needs could
overcome these barriers.
The exercise program is novel. It incorporates all ele-
ments of the “Activity Pyramid” [92]: lifestyle activity;
aerobic activity, strength and flexibility. It incorporates
the notion of a “push-day” when persons are encouragedto push themselves to exercise intensely for short bursts.
It is designed to add some form of exercise to most
days.
In addition, this trial incorporates a number of statis-
tical approaches rarely applied in the rehabilitation field,
yet this field typically conducts research that would
benefit from more modern statistical and methodo-
logical approaches.
The primary outcome is binary not a difference of two
means. This is a more interpretable outcome and facili-
tates knowledge translation as people with MS and their
care providers can readily understand what proportion
of people made a relevant gain, whereas a mean differ-
ence may not apply to individual subjects. This outcome
permits a calculation of number-needed-to-treat (NNT)
[93], a very useful statistic in terms on comparative
effectiveness [94]. With this outcome, it is also possible
for research results to present data showing factors in-
creasing the probability of a positive response permitting
participants and providers alike to identify whether an
individual is in a group more or less likely to benefit and
perhaps provide additional interventions to increase
probability of response.
All secondary outcomes will be analysed using a global
response statistic. A challenge with trials of complex in-
terventions particularly those which tailor the interven-
tion to patient needs, which typify rehabilitation-type
interventions, is that no one outcome is likely to capture
the effect equally for each person and analysing each
outcome separately is often considered suspect in some
research cultures. Recently in a 2009 publication in the
Archives of Physical Medicine and Rehabilitation, Bagiella
[85] demonstrates the value of using modern statistical
methods to combine multiple outcomes into a composite
response variable. We have demonstrated the benefit of
this approach in evaluating a case-management interven-
tion for people discharged home post-stroke [95].
We will also use propensity scoring, a widely used epi-
demiologic method to improve validity and precision
when there is a need to consider multiple confounders
that also may be correlated; a propensity score is calcu-
lated for each person based on their probability of taking
an action or treatment, here engaging in exercise. Using
this method, the propensity score is the adjustment vari-
able, either as a continuous variable or a categorical vari-
able such as quintiles (depending on linearity). The
advantage is that multiple confounders can be combined
in a single propensity score; adjustment in the analysis
for the single propensity score also adjusts for all the
confounders summarized in the score [89].
The results of the trial will contribute needed evi-
dence for the development of guidelines for exercise
for MS. If proven effective, the content will be made
available at no cost.
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